Dynavax Technologies (NASDAQ:DVAX – Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05, Zacks reports. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%.
Dynavax Technologies Price Performance
Shares of DVAX remained flat at $13.33 during trading hours on Friday. The stock had a trading volume of 2,869,831 shares, compared to its average volume of 1,660,510. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $1.75 billion, a P/E ratio of 74.06 and a beta of 1.32. The business’s 50 day moving average is $12.81 and its two-hundred day moving average is $11.99. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.05.
Wall Street Analyst Weigh In
Several research firms have commented on DVAX. The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a report on Friday. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday. Finally, StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
- Five stocks we like better than Dynavax Technologies
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What Are Dividends? Buy the Best Dividend Stocks
- DuPont’s Electronics Spinoff: The Start of Something Big
- The 3 Best Retail Stocks to Shop for in August
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
